ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)
Open accessThe DOI matches its Crossref record.
Abstract
Biologics have become key agents for the management of Crohn's disease and ulcerative colitis. Biosimilars are biological medicines similar to previously authorized biologics and are already available in some countries. This ECCO Position Statement defines the collective view of European specialist in inflammatory bowel disease (IBD) concerning biosimilars. Biosimilars are not comparable to generic small molecules, since both efficacy and toxicity are difficult to predict due to subtle molecular changes that can have profound effects on clinical efficacy and immunogenicity. Direct evidence of safety and benefit from clinical trials in IBD, post-marketing pharmacoviligance, and unequivocal identification of the product as a biosimilar should be requirements before approval. Switching from an established biologic to a biosimilar to save costs is likely to be as inappropriate and inefecctive as switching between current biologics that act on the same target, except when there is loss of response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ungaro, R., Mehandru, S., Allen, P. B., Peyrin-Biroulet, L., & Colombel, J.-F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32126-2 · Cited by 3,531
Jørgensen, K. K., Olsen, I. C., Goll, G. L., Lorentzen, M., Bolstad, N., Haavardsholm, E. A., Lundin, K. E. A., Mørk, C., Jahnsen, J., Kvien, T. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30068-5 · Cited by 818
Biosimilars: the science of extrapolation
Weise, M., Kurki, P., Wolff-Holz, E., Bielsky, M.-C., & Schneider, C. K. (2014) · Blood · doi:10.1182/blood-2014-06-583617 · Cited by 307
Meijboom, R. W., Gardarsdottir, H., Egberts, T. C. G., & Giezen, T. J. (2022) · BioDrugs · doi:10.1007/s40259-021-00508-4 · Cited by 18
Metadata
- Authors
- Danese, S., Gomollon, F., & on behalf of the Governing Board and Operational Board of ECCO
- Venue
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-08-01
- Volume
- 7
- Issue
- 7
- Pages
- 586-589
- ISSN
- 1873-9946 (ISSN-L)
- 1876-4479
- OpenAlex
- W2149858688
- Cited by
- 192
- References
- 0
- FWCI
- 12.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). https://app.cochat.ai/papers/10.1016/j.crohns.2013.03.011
- The paper
- Danese, S., Gomollon, F., & on behalf of the Governing Board and Operational Board of ECCO. (2013). ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). Journal of Crohn's and Colitis. https://doi.org/10.1016/j.crohns.2013.03.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.